secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0001104659-22-072157
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE completes Phase 2a enrollment for FMX114; extends In4Derm Oral BETi option to Feb 2023
--------------------------------------------------------------------------------

- Enrollment completed in Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis; top-line results expected in 6-8 weeks.
- Option term for Oral BETi Compounds extended to Feb 28, 2023; VYNE to pay In4Derm £300,000 by June 30, 2022.
- Upon discovery of two Oral BETi Compounds with specified molecular profile, VYNE to pay In4Derm additional £850,000.
- Previous Phase 1b segment showed statistically significant reduction in ADSI score and pruritus with FMX114 vs vehicle.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922072157/0001104659-22-072157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465922072157/tm2218445d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-072157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer